Curve Therapeutics, a Southampton, UK-based non-public biotechnology firm, raised $40.5M in Sequence A funding.
The spherical was led by Pfizer Ventures with participation from Columbus Enterprise Companions and British Affected person Capital, which joined founding investor Creation Life Sciences and co-lead from the seed spherical, Epidarex Capital.
The corporate intends to make use of the funds to progress improvement of those belongings quickly in direction of scientific improvement and to develop the invention platform past difficult and sophisticated intracellular protein targets.
Led by CEO Simon Kerry, Curve Therapeutics is a biotechnology firm offering an intracellular screening platform to allow the invention of progressive therapeutics that handle complicated and difficult illness targets with the potential to rework the lives of sufferers.
Its Microcycle® platform allows the direct discovery of biologically energetic molecules towards targets which have been troublesome to deal with utilizing standard drug discovery strategies. Curve has constructed a discovery pipeline of belongings together with a first-in-class dual-inhibitor of HIF-1 and HIF-2 that addresses survival mechanisms in additional than half of strong tumours, and a first-in-class inhibitor of ATIC dimerization that targets an essential vulnerability in a number of cancers.
FinSMEs
27/02/2024
